Abstract Number: 1506 • 2018 ACR/ARHP Annual Meeting
Synovial Tissue Histopathology Findings in EARLY RA. Is It Usefull? Analysis of the Belgian CAP48 Cohort
Background/Purpose: The development of ultrasound (US) guided synovial biopsy will enable synovial tissue collection from small joints and will facilitate histopathological studies, thus improving the…Abstract Number: 1507 • 2018 ACR/ARHP Annual Meeting
Predictors of Fatigue and Persistent Fatigue in Early Rheumatoid Arthritis: A Longitudinal Observational Study
Background/Purpose: Fatigue is a multifactorial and persistent symptom reported by patients with rheumatoid arthritis (RA). It is considered as frequent as pain. It would be…Abstract Number: 1508 • 2018 ACR/ARHP Annual Meeting
Relationship between BMI and Lower Limb Dysfunction in Japanese Female Patients with Rheumatoid Arthritis (the data from NinJa registry)
Background/Purpose: To clarify the relationship between Body Mass Index (BMI) and lower limb dysfunction in patients with rheumatoid arthritis (RA). Methods: The data of 8,332…Abstract Number: 1509 • 2018 ACR/ARHP Annual Meeting
Associations between Perceived Stress and Joint Signs in an Anti-Cyclic Citrullinated Peptide Antibody Positive at-Risk Population
Background/Purpose: Psychosocial factors have been associated with rheumatoid arthritis (RA) outcomes, but have not been well characterized in the early development of RA. We examined…Abstract Number: 1510 • 2018 ACR/ARHP Annual Meeting
Depression Is a Major Driver of Functional Capacity in Patients with Rheumatoid Arthritis Regardless of Disease Activity
Background/Purpose: Depression is one of the most frequent comorbidity in RA patients. It´s presence is associated with higher healthcare costs, mortality rate and reduced odds…Abstract Number: 1511 • 2018 ACR/ARHP Annual Meeting
The Relationship between Lipid Profile Changes and Inflammation across the Phase 3 Sarilumab Rheumatoid Arthritis (RA) Developmental Program
Background/Purpose: Sarilumab showed superiority to placebo and adalimumab in Phase 3 trials. Serum lipids may be reduced in the setting of chronic inflammation associated with…Abstract Number: 1512 • 2018 ACR/ARHP Annual Meeting
Reduction in Power Doppler Ultrasound Score with Tocilizumab Treatment Associates with Improvement in the Protective Profile of HDL in Patients with Rheumatoid Arthritis
Background/Purpose: Musculoskeletal ultrasound (MSUS) can detect synovitis by Power doppler (PDUS) and can predict erosive progression on xrays in rheumatoid arthritis (RA) patients. We previously…Abstract Number: 1513 • 2018 ACR/ARHP Annual Meeting
Efficacy of Etanercept By Body Mass Index in Women and Men with Rheumatoid Arthritis: A Post Hoc Analysis of Three Randomized Trials
Background/Purpose: In patients with RA treated with TNF-α inhibitors, a higher BMI has been associated with lower odds of achieving disease remission. We evaluated the…Abstract Number: 1514 • 2018 ACR/ARHP Annual Meeting
Impact of Comorbidity Burden and Obesity on the Effectiveness of Tocilizumab in Patients with Rheumatoid Arthritis
Background/Purpose: Few real-world studies have evaluated the impact of comorbidity burden or obesity on the effectiveness of tocilizumab (TCZ) for the improvement of rheumatoid arthritis…Abstract Number: 1515 • 2018 ACR/ARHP Annual Meeting
Malignancy in Japanese Patients with Rheumatoid Arthritis Treated with Tofacitinib: Interim Analysis of All-Case Post-Marketing Surveillance
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The efficacy and safety of tofacitinib have been demonstrated in patients (pts)…Abstract Number: 1516 • 2018 ACR/ARHP Annual Meeting
Infection Events in Japanese Patients with Rheumatoid Arthritis Treated with Tofacitinib: Interim All-Case Post-Marketing Surveillance
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Previously, the efficacy and safety of tofacitinib were demonstrated in patients (pts)…Abstract Number: 1517 • 2018 ACR/ARHP Annual Meeting
Integrated Safety Analysis across Phase 3 Clinical Studies Including the Controlled and Uncontrolled Periods for Intravenous Golimumab in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Background/Purpose: The GO-FURTHER, GO-VIBRANT, and GO-ALIVE randomized controlled trials evaluated the efficacy and safety of intravenous (IV) golimumab (GLM) in patients (pts) with active rheumatoid…Abstract Number: 1518 • 2018 ACR/ARHP Annual Meeting
Baricitinib and Tofacitinib in Real Life – Does Obesity Impact Response to Janus Kinase Inhibitor Therapy in Rheumatoid Arthritis?
Background/Purpose: The influence of obesity on treatment response of tumor necrosis factor inhibitors in patients with rheumatoid arthritis (RA) is described in literature, but data…Abstract Number: 1519 • 2018 ACR/ARHP Annual Meeting
Patient Characteristics Associated with Discontinuation of Tofacitinib for the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. We explored characteristics of patients (pts) who discontinued (d/c) open-label, long-term extension…Abstract Number: 1520 • 2018 ACR/ARHP Annual Meeting
DMARD Hepatotoxicity in Rheumatoid Arthritis and Its Association with the Surrogates of Metabolic Syndrome
Background/Purpose: Hepatotoxicity is a common reason why DMARDs are abandoned or changed in RA. We hypothesize that features of metabolic syndrome (such as obesity, dyslipidemia,…
ACR Meeting Abstracts